# Study of ALTO-101 in Patients With Schizophrenia

> **NCT06502964** · PHASE2 · RECRUITING · sponsor: **Alto Neuroscience** · enrollment: 82 (estimated)

## Conditions studied

- Schizophrenia
- Cognitive Impairment

## Interventions

- **DRUG:** ALTO-101
- **DEVICE:** ALTO-101 Transdermal Delivery System
- **DRUG:** Placebo
- **DEVICE:** Placebo Transdermal Delivery System

## Key facts

- **NCT ID:** NCT06502964
- **Lead sponsor:** Alto Neuroscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2026-02
- **Final completion:** 2026-03
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06502964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06502964, "Study of ALTO-101 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06502964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*